Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation

American Journal of Hypertension

Volumn 22, Issue 10, 2009, Pages 1101-1106

  Lu, Hongmei ^a   Kanazawa, Masayuki ^a   Ishida, Atsuko ^a   Tufescu, Andreia ^a   Sasaki, Yuko ^a   Ito, Osamu ^a   Kurosawa, Hajime ^a   Sato, Toshinobu ^b   Ootaka, Tetsuya ^c   Kohzuki, Masahiro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c Katta General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AZELNIDIPINE; CREATININE; OLMESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; MALE; MONOTHERAPY; NEPHRECTOMY; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; SHAM PROCEDURE; THERAPY EFFECT; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

ABLATION TECHNIQUES; ACTINS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AZETIDINECARBOXYLIC ACID; BLOOD UREA NITROGEN; COMBINED MODALITY THERAPY; CREATININE; DIHYDROPYRIDINES; EXERCISE THERAPY; IMIDAZOLES; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; PROTEINURIA; RATS; RATS, INBRED WKY; TETRAZOLES;

EID: 70349470963     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.148     Document Type: Article

References (36)

1. Wasserman K. Physiology of exercise. In Wasserman K, Hansen JE, Sun DY, Whipp BJ (eds), Principles of Exercise Testing and Interpretation. Lippincott Williams & Wilkins: Philadelphia, 1999, pp. 10-61.
2. Goldberg A P, Geltman EM, Gavin JR, Carney RM, Hagberg JM, Delmez JA, Naumovich A, Oldfield MH, Harter HR. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. Nephron 1986; 42:311-316.
3. Carney RM, McKevitt PM, Goldberg A P, Hagberg J, Delmez JA, Harter HR. Psychological effects of exercise training in hemodialysis patients. Nephron 1983; 33:179-181.
4. Clyne N, Ekholm J, Jogestrand T, Lins LE, Pehrsson SK. Effects of exercise training in predialytic uremic patients. Nephron 1991; 59:84-89.
5. Kohzuki M, Kamimoto M, Wu XM, Xu HL, Kawamura T, Mori N, Nagasaka M, Kurosawa H, Minami N, Kanazawa M, Saito T, Yoshida K. Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. J Hypertens 2001; 19:1877-1882. (Pubitemid 32924956)
6. Kanazawa M, Kawamura T, Li L, Sasaki Y, Matsumoto K, Kataoka H, Ito O, Minami N, Sato T, Ootaka T, Kohzuki M. Combination of exercise and enalapril enhances renoprotective and peripheral effects in rats with renal ablation. Am J Hypertens 2006; 19:80-86.
7. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51:1908-1919. (Pubitemid 27252762)
8. Yoshida K, Xu HL, Kawamura T, Ji L, Kohzuki M. Chronic angiotensin-converting enzyme inhibition and angiotensin II antagonism in rats with chronic renal failure. J Cardiovasc Pharmacol 2002; 40:533-542.
9. Kurashige T, Abe K, Furusu A, Miyazaki M, Obata Y, Xia Z, Nakazawa M, Nakazawa Y, Funakoshi S, Harada T, Koji T, Kohno S. Renoprotective effect of azelnidipine in rats. Biol Pharm Bull 2008; 31:2237-2244.
10. Ohki-Hamazaki H, Watase K, Yamamoto K, Ogura H, Yamano M, Yamada K, Maeno H, Imaki J, Kikuyama S, Wada E, Wada K. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature 1997; 390:165-169.
11. Ikeda K, Nara Y, Yamori Y. Indirect systolic and mean blood pressure determination by a new tail cuff method in spontaneously hypertensive rats. Lab Anim 1991; 25:26-29.
12. Tufescu A, Kanazawa M, Ishida A, Lu H, Sasaki Y, Ootaka T, Sato T, Kohzuki M. Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy. J Hypertens 2008; 26:312-321.
13. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco P, Remuzzi G. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995; 26:934-941.
14. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997; 8:1537-1545.
15. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998; 53:1608-1615.
16. Kaneko Y, Sakatsume M, Xie Y, Kuroda T, Igashima M, Narita I, Gejyo F. Macrophage metalloelastase as a major factor for glomerular injury in anti-glomerular basement membrane nephritis. J Immunol 2003; 170:3377-3385.
17. Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60:957-968.
18. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 1986; 122:481-487.
19. Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005; 16:1013-1023.
20. Pilmore HL, Painter DM, Bishop GA, McCaughan GW, Eris JM. Early up-regulation of macrophages and myofibroblasts: a new marker for development of chronic renal allograft rejection. Transplantation 2000; 69:2658-2662.
21. Bergamaschi CT, Boim MA, Moura LA, Piçarro IC, Schor N. Effects of long-term training on the progression of chronic renal failure in rats. Med Sci Sports Exerc 1997; 29:169-174.
22. Gleim GW. Renal response to exercise and training. In Garrett WE Jr, Kirkendall DT (eds), Exercise and Sport Science. Lippincott Williams & Wilkins: Philadelphia, 2000, pp. 217-225.
23. Osato S, Onoyama K, Okuda S, Sanai T, Hori K, Fujishima M. Effect of swimming exercise on the progress of renal dysfunction in rat with focal glomerulosclerosis. Nephron 1990; 55:306-311.
24. Heifets M, Davis TA, Tegtmeyer E, Klahr S. Exercise training ameliorates progressive renal disease in rats with subtotal nephrectomy. Kidney Int 1987; 32:815-820.
25. Cornacoff JB, Hebert LA, Sharma HM, Bay WH, Young DC. Adverse effect of exercise on immune complex-mediated glomerulonephritis. Nephron 1985; 40:292-296.
26. Rett K, Wicklmayr M, Dietze GJ. Metabolic effects of kinins: historical and recent developments. J Cardiovasc Pharmacol 1990; 15 Suppl 6:S57-S59.
27. Anderson S. Antihypertensive therapy in experimental diabetes. J Am Soc Nephrol 1992; 3:S86-S90.
28. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155:1073-1080.
29. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992; 41:297-309.
30. Junaid A, Rosenberg ME, Hostetter TH. Interaction of angiotensin II and TGF-beta 1 in the rat remnant kidney. J Am Soc Nephrol 1997; 8:1732-1738.
31. Hashimoto N, Maeshima Y, Satoh M, Odawara M, Sugiyama H, Kashihara N, Matsubara H, Yamasaki Y, Makino H. Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol 2004; 286:F516-F525.
32. Fujiwara Y, Kitamura E, Ueda N, Fukunaga M, Orita Y, Kamada T. Mechanism of action of angiotensin II on isolated rat glomeruli. Kidney Int 1989; 36:985-991.
33. Sluiter HE, Wetzels J F, Huysmans FT, Koene RA. The natriuretic effect of the dihydropyridine calcium antagonist felodipine: a placebo-controlled study involving intravenous angiotensin II in normotensive volunteers. J Cardiovasc Pharmacol 1987; 10 Suppl 10:S154-S161.
34. Takahashi T, Konta T, Takasaki S, Ichikawa K, Takeishi Y, Kubota I. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy. Clin Exp Nephrol 2007; 11: 202-208.
35. Kanazawa M, Kohzuki M, Yoshida K, Kurosawa H, Minami N, Saito T, Yasujima M, Abe K. Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation. Hypertens Res 2002; 25:447-453.
36. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333:321-326.